adenoma extends beyond the sella turcica. Naturally, when a tumour extends farther, a fuller exposure is necessary. Should a frontal extension exist, the exposure of the frontal pole must be such as to permit of its resection, if necessary. Extension into the middle fossa needs a wider exposure of the temporal lobe.
The transsphenoidal operation is a surgical approach which should be restricted to cases where the growth does not extend beyond the diaphragma selhe. It is useful, therefore, in cases of acromegaly, for hypophysectomy in the relief of disseminated carcinomatosis, and where tumours erode the base of the skull, encroaching on the sphenoidal sinus, the nose, or the nasopharynx. Hypopituitarism must be counteracted by appropriate endocrine replacement both before and after operation. This permits one to operate upon cases of extended tumours with much less apprehension on the part of the surgeon, and much greater tolerance on the part of the patient.
Deep X-ray therapy should not be looked upon as a primary method of treatment unless some contraindication to operation exists, e.g. a disorder of general health, or if the patient refuses operation. On the other hand, operative treatment should always be followed by a course of deep X-ray therapy in adenomatous tumours.
I am very doubtful whether any benefit accrues from applying deep X-ray therapy in cases of craniopharyngioma. Of recent years, efforts have been made to treat craniopharyngiomata by the implantation of radioactive isotopes, particularly gold. Even ,-radiation has been tried in the implantation of yttrium seeds, with a view to direct destruction of tumour tissue. Such methods are still experimental.
Dr J A C Fleming (Radiotherapy Department, St Thomas's Hospital, London) Treatment ofPituitary Tumours by External Irradiation Most patients with pituitary tumours sent for external irradiation have chromophobe adenomata. Of 220 cases reviewed by Richmond (1958) about 80% belonged to this category; 8% were cases of eosinophil tumour.
Recent reports confirm previous impressions that the radiosensitivity of these tumours varies in proportion to the magnitude of the radiation dose delivered to the gland. Colby et al. (1964) and Paterson (1963) mentioned difficulties in evaluating the response to treatment of chromophobe adenoma in terms of measurable criteria, other than changes in visual field impairment.
Over the last fourteen years, two methods of external irradiation have been used at St Thomas's Hospital:
(1) Initially by orthovoltage 250 kV X-rays, employing narrow beams of about 5 cm crosssectional diameter. After accurate localization of the sella to reference marks on the skin, checked radiologically, the beams were directed through five or six skin fields around the scalp and aimed to 'cross fire' the sella.
(2) Since 1957 similarly narrow beams of y-rays from a cobalt teletherapy unit have been used. Although slightly heavier doses are applied with y-rays to compensate for their less damaging effect upon all tissues, as compared with orthovoltage X-rays, evidence to suggest that the y-rays exert superior biological effects upon these tumours is lacking. Greater physical penetration of cobalt y-rays through tissue with much reduced skin damage has, however, enabled adequate tumour dosage to be delivered through only three skin fields, with resulting increased accuracy, negligible skin reaction and less disturbance to the patient.
Patients Treated
Forty patients with pituitary tumours have been treated by radiotherapy over the last ten years. Information is available on the progress of only 23 of these for one year or more following treatment. Eighteen of the 23 had chromophobe or mixed tumours and all except 5, of whom 3 were acromegalic, were referred after some form of operative surgery. Conclusions on efficacy of treatment cannot be drawn from such limited material, but the control rate does not seem to differ materially from other published results.
Dosage and Complications
Before 1953 pituitary adenomata were treated by orthovoltage X-rays to total average tumour doses of about 4,000-5,000 rads given in twenty fractions over about twenty-eight days, without any known complications. From 1953 to 1957 this dose rarely exceeded 4,200 rads.
In August 1957 a patient was referred to me with an eight-year history of acromegaly associated with a pituitary adenoma; no surgery had been undertaken. An ophthalmologist suspected some impaired vision affecting the upper temporal quadrants; otherwise the eyes were normal. Because of recent activity, the tumour was given a dose of 4,300 rads with cobalt y-rays in twelve fractions over twenty-three days; estimated to be equivalent to about 4,500 rads given in twenty fractions over twenty-eight days using orthovoltage X-rays.
After satisfactory clinical remission the patient developed defective vision in one eye about fourteen months later. Exploratory craniotomy for suspected recurrence revealed no evidence of tumour, but atrophy of the optic tracts, regarded as secondary to radiation damage. There was no evidence of injury to other related structures.
Since this episode Jackson Richmond (1958) , Crompton & Layton (1961 ), Bignami et al. (1963 and Almquist et al. (1964) have reported other cases of radiation damage not only to the optic chiasma, but also severe and fatal damage to the related hypothalamic region, following doses of radiation to the pituitary of similar magnitude.
Almquist et al. (1964) comment on the relative radioresistance of the optic chiasma and tracts in contrast to the hypothalamus and white brain tissue and -refer to doses of about 100,000 r n-radiation, from implanted radio-yttrium seeds which were required to cause optic tract damage in monkeys. They consider that estimates of radiation dosage which produce radionecrosis of the optic nerve should remain open pending further investigations.
A case of optic nerve damage only, from external irradiation, has been reported by Lawrence et al. (1963) two years after ablation of the pituitary for breast cancer, using a narrow beam of ac-particles from a 900 MeV accelerator. Pituitary doses of about 15,000 rads are given in six treatments over eleven days, which may, by estimate, amount to four or five times the maximum equivalent dose given by X-or y-rays to a pituitary adenoma.
These workers have also irradiated the pituitary with a-particles for acromegaly and Cushing's disease, but the -fuil -value *of' this method, involving the use of very costly equipment, has yet to be assessed.
Experience with a relatively small number of patients confirms that most cases of pituitary tumour sent for radiotherapy are chromophobe adenomata. Corroboration by Horrax (1958) and Sheline et al. (1964) of the earlier findings of , that irradiation after surgery significantly increased the control rate, suggests that the combined attack is still to be preferred to surgery alone. There is as yet insufficient evidence of their radiosensitivity to warrant irradiation only of these adenomata, in preference to surgery: this however, may not apply with the same force to eosinophil tumours.
Although response to irradiation of pituitary adenomata increases with size of dose, a slight risk of radiation damage to the hypothalamic region and optic tracts seems to exist when doses exceed the equivalent of about 4,500 rads delivered to the gland with orthovoltage X-rays in twenty fractions over twenty-eight days. A maximum dose of 3,750 r (3,650 rads) over a similar period as suggested by Jackson Richmond (1958) Pituitary Implantation for Pituitary Tumours Radioactive implantation of the pituitary by the transnasal route has now been used to treat 361 patients, most of whom had advanced cancer of the breast (Table 1 ). In most, two sources of yttrium-90 have been implanted in an attempt to achieve complete pituitary ablation. This isotope, which emits 3-particles only, can be implanted. safely and simply by the screw technique (Forraest
